Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

Review Article

Cannabinoids in the Treatment of Epilepsy

List of authors.
  • Daniel Friedman, M.D.,
  • and Orrin Devinsky, M.D.

The pharmacologic and biochemical features of cannabinoids make them candidates for antiseizure medications. At this time, anecdotes have outstripped controlled clinical trials as sources of support for their clinical value.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

Dr. Devinsky reports receiving grant support from GW Pharmaceuticals and Novartis and serving on the scientific advisory board of MiaMed; and Dr. Friedman, receiving fees for serving on an advisory board for Marinus Pharmaceuticals and consulting fees from Eisai, Marinus Pharmaceuticals, SK Biopharmaceuticals, Upsher-Smith Laboratories, and Pfizer, all of which were paid to the Epilepsy Study Consortium. No other potential conflict of interest relevant to this article was reported.

Author Affiliations

From the Department of Neurology, New York University Langone School of Medicine, New York.

Address reprint requests to Dr. Friedman at the Department of Neurology, NYU Langone School of Medicine, 223 E. 34th St., New York, NY 10016, or at .

Print Subscriber? Activate your online access.